As a novel cancer immunotherapy with high market price, chimeric antigen receptor T cell (CAR-T) has not been marketed for a long time, and its clinical usage is difficult to predict precisely. Currently it has not been included in the National Reimbursement Drug List (NRDL). Based on the analysis of the difficulties in reimbursing CAR-T products, combining the medical insurance management system in China, the paper proposed to establish a four-step settlement mode for CAR-T products, and brought forward three key points of “coordination between price and volume - collaborating with commercial health insurance - advance negotiation” from the practical side, to ensure the implementation of the innovative payment mode, reduce the risk of medical insurance fund expenditure, and improve the accessibility of CAR-T products.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |